Wegovy having no effect: what's actually going on

Step 1, Check where you actually are in the titration

The single most common reason people feel Wegovy is doing nothing is that they are still in the early stages of dose escalation. The titration ladder runs 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, with roughly four weeks at each level. The opening dose is there to let your body adjust, not to suppress appetite strongly. Clinical appetite effects tend to become noticeable for most people somewhere around the 0.5–1.0 mg phase, and meaningful weight change generally requires the 1.7–2.4 mg range over an extended period.

The STEP 1 trial, published in the New England Journal of Medicine, followed participants for 68 weeks at the 2.4 mg maintenance dose and found an average weight reduction of around 15%. That figure covers the full treatment period, the curve is not a straight line. Expecting a two-pen response that matches a 68-week outcome sets an unfair benchmark. If you are in the first three months, you may simply not be at the dose yet where the medicine can do its job.

For a closer look at when Wegovy tends to take effect and how the timeline typically unfolds, most people find it maps out what to expect at each stage. Worth reading before drawing conclusions.

Step 2, Run a quick check on technique and storage

Once you are satisfied the timeline is not the issue, technique and storage are the next things to audit. This takes under a minute. Check three things: first, that pens have been stored in the fridge at 2–8°C and not frozen; second, that you are rotating injection sites (abdomen, outer thigh and upper arm are the licensed options) rather than reusing the same spot repeatedly; third, that the pen is primed and the dose is fully delivered before withdrawing. Subcutaneous injections into a site with significant lipohypertrophy (tissue that has hardened from repeated needling in the same place) can reduce absorption noticeably.

Storage matters more than people expect. A pen that has been left out of the fridge for longer than the window stated in the Patient Information Leaflet should not be used; the SmPC, available on the electronic Medicines Compendium, gives the exact room-temperature window for Wegovy. When in doubt, contact your prescriber rather than self-deciding a pen is still usable.

Missed doses are worth noting too. Wegovy's half-life means a single missed week does not wipe out all progress, but a pattern of late or skipped doses will blunt the overall effect. Your prescriber, not the Patient Information Leaflet alone, is the right person to advise on what to do if a dose has been missed.

Step 3 (Consider biological and lifestyle factors that can limit response

Some people experience a genuinely attenuated response to GLP-1 medicines at a biological level) this is not a character flaw or a lack of effort. Research into non-response to semaglutide, the active ingredient in Wegovy, is ongoing, but a few factors are consistently associated with a smaller-than-average result: very high baseline caloric intake that offsets reduced appetite; certain medications that affect appetite or weight (some antidepressants, corticosteroids and antipsychotics, for example); and metabolic conditions that complicate energy regulation. These are clinical conversations, not things to self-diagnose from a checklist.

The NHS medicines page for semaglutide sets out the expected side-effect and effectiveness profile in patient-facing language. If your experience diverges significantly from what it describes, that divergence itself is useful clinical information for your prescriber. Keeping a brief weekly log of appetite changes, meal sizes and any side effects gives your prescriber something concrete to work with rather than a general impression.

It is also worth reading about the range of effects Wegovy can have on appetite, food noise and portion tolerance, since these often precede measurable weight change and are signs the medicine is working, even when the number on the scale has not shifted yet. Understanding how the effect of Wegovy tends to build across different body systems can also help you recognise changes you might otherwise overlook. If you have noticed changes to your menstrual cycle, our page on how Wegovy can affect your period covers what is known about that too.

Step 4, Know when the answer is a clinical review, not more waiting

NICE guidance on semaglutide (TA875) states that if someone has lost less than 5% of their body weight after six months at the highest tolerated maintenance dose, the case for continuing should be formally reviewed. That is a clinical benchmark, not an arbitrary rule. It protects patients from staying on a medicine that is genuinely not working for them, while also recognising that a slow response in the early months reflects how Wegovy's time to effect works across the titration period, rather than indicating no response at all.

If you are approaching that threshold, a prescriber review is the appropriate route. At nume, every repeat order goes through a clinical re-review; our prescribers (you can read about our clinical team's approach to treatment) can assess whether a dose adjustment, a switch, or a wider conversation about your treatment plan is the right step. No repeat goes out on autopilot. If you have questions in the meantime, our support team is available seven days a week.

Thinking about whether Wegovy is right for you, or whether a different approach might fit better? Our weight-loss treatment overview compares the options. And if you are ready to speak to a prescriber, a free consultation is the place to start.